Marker Therapeutics Inc (MRKR)

[hanscott]

I too hope the optimism proves correct :). The changes they made are substantial and should only make the therapy more effective.

As for the funding part - I guess the big questions are: 1) when do they need to go after the funding, 2) what is the share price then and 3) what data can we expect to see that could alter the share price between now and then?

For #1, in the 3Q Report in November they said they had enough cash to make it into Q1, 2023 (good thing they got the $13.1 million grant for the AML P2 in August from the Cancer Prevention and Research Institute of Texas!).

For #3, Data betwixt now and then - according to the Feb 16 Update, slides 31 and 40 we: a)__should get a preliminary top-line readout on the Active Group using the old protocol sometime soon (Q1/Q2), and b)__ hopefully have some data for the 6 patients in the cohorts testing the higher cell doses using the 9-day manufacturing process by Q3.

For #2, the share price when they go for more funding: I have low expectations for the top-line Active Group data using the old protocol, but I have high expectations for 9-day, higher cell dose process which we should hear about in Q3/4.

< If > the results are impressive for the new high dose, 9-day process, they should be able to easily get funding and at a "substantially improved" share price from here (ffs almighty).